French firm Gecko Biomedical has obtained CE-Mark to market its SETALUM Sealant in Europe.

The sealant is a biocompatible, bioresorbable on-demand activated polymer designed for use as an add-on to sutures in vascular surgery and can be activated with the firm’s light activation pen.

Based on natural adhesive mechanisms, the sealant features a bio-inspired technology developed by the Massachusetts Institute of Technology, Harvard Medical School, and Brigham and Women’s Hospital.

Gecko Biomedical CEO Christophe Bancel said: “Our ability to bring an entirely new family of innovative polymers from the bench to the bedside in less than two and a half years is a testimony to the versatility and scalability of our platform.

“We are now ready to fully expand, internally and through partnerships, into new therapeutic areas to design disruptive, surgical solutions for patients.”

"We are now ready to fully expand, internally and through partnerships, into new therapeutic areas to design disruptive, surgical solutions for patients."

The firm validated the safety and performance of the sealant in a prospective, single-arm and multi-centre clinical study (BlueSeal) at four university hospitals in the country.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BlueSeal included 22 patients who required carotid endarterectomy and assessed the polymer’s performance through immediate haemostasis percentage after clamp removal.

The results demonstrated optimal safety profile and immediate haemostasis in 85% patients without adverse sealant-related incidents.

BlueSeal principal investigator Jean-Marc Alsac said: “The SETALUM sealant can be precisely and easily applied thanks to its viscosity and hydrophobicity, and then activated at will to provide an instant hermetic barrier and effective haemostasis.”

Gecko has increased its manufacturing capabilities for the sealant and is working towards expanding applications for new functionalities, tissue types, clinical indications, and geographic markets.